Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Raw Materials (2018 - 2022)

AVITA Medical filings provide 5 years of Raw Materials readings, the most recent being $1.1 million for Q4 2022.

  • On a quarterly basis, Raw Materials fell 7.45% to $1.1 million in Q4 2022 year-over-year; TTM through Dec 2022 was $1.1 million, a 7.45% decrease, with the full-year FY2022 number at $1.1 million, down 7.45% from a year prior.
  • Raw Materials hit $1.1 million in Q4 2022 for AVITA Medical, down from $1.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.2 million in Q4 2021 to a low of $589691.6 in Q2 2018.
  • Median Raw Materials over the past 5 years was $964500.0 (2020), compared with a mean of $913402.2.
  • Biggest five-year swings in Raw Materials: surged 55.57% in 2020 and later dropped 7.45% in 2022.
  • AVITA Medical's Raw Materials stood at $589691.6 in 2018, then increased by 3.23% to $608721.6 in 2019, then soared by 55.57% to $947000.0 in 2020, then rose by 29.04% to $1.2 million in 2021, then decreased by 7.45% to $1.1 million in 2022.
  • The last three reported values for Raw Materials were $1.1 million (Q4 2022), $1.2 million (Q4 2021), and $982000.0 (Q2 2021) per Business Quant data.